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Objectives: In situ formation of nanocrystals and dissolution profiles of fenofibrate (FFB) from 
a self-microemulsifying drug delivery system (SMEDDS) were characterized.
Methods: SMEDDS formulated with Myritol® and surfactant mixture (Smix) of D-α-Tocopheryl 
polyethylene glycol 1000 succinate (TPGS) and either Tween® 20 (A, C, E, G, M, S, N, T, O) 
or Tween® 80 (B, D, F, H, P, U, Q, V , R) at various oil/Smix ratios (Group I: A and B of 0.42, C 
and D of 0.25, E and F of 0.11; Group II: G and H of 1.38, M and P of 1.11, S and U of 0.9, N 
and Q of 0.73, T and V of 0.58, and O and R of 0.46) and water contents (1: 9.5%, 2: 5.0%, 3: 
0.0%, G–V: 4.5%). Their dissolutions were conducted at different rotation speeds. Two optimal 
SMEDDSs containing Tween 80(B2) or a higher oil/Smix ratio(Q) and B2(solution) were selected 
for pharmacokinetic study.
Results: FFB particles formed within the nanosize range from Group I gradually increased 
with time but decreased with increasing stirring rates. However, the mean size of FFB formed 
by B series was as low as 200 nm, which was smaller than that of A series at three stirring rates. 
The release rate from both groups obviously increased with increasing stirring rate. However, 
incomplete release was observed for S and N in Tween 20 series, whereas a faster release rate 
and complete release were observed for Tween 80 series with an insignificant difference among 
them. Results of pharmacokinetic study demonstrated that the highest-ranked area under the curve 
and Cmax values were for Q(SMEDDS) and B2(solution), respectively. The relative   bioavailability 
of Q(SMEDDS) with respect to Tricor® was enhanced by about 1.14–1.22-fold.
Conclusion: SMEDDS, consisting of Myritol 318 and TPGS combined with Tween 80 at 4:1, 
was able to enhance the oral bioavailability of FFB.
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Introduction
Since microemulsions were first introduced some 60 years ago by Hoar and Schuaman,1 
many applications have been found, especially for improving the oral bioavailability 
of poorly soluble drugs and nutraceuticals.2 Currently, water/oil (w/o) types of 
microemulsions,3 or oil/water (o/w) microemulsions separated by a two-phase region,4,5 
self-microemulsifying drug delivery system (SMEDDS),6–8 and U-type phase diagrams 
capable of forming microemulsions at any given water dilution level (U-type precon-
centrate) have been utilized to solubilize and increase the bioavailability of drugs and 
nutraceuticals.9–13 W/o or o/w microemulsions are excellent and effective carriers 
that increase the solubility and improve the bioavailability of poorly water-soluble 
drugs.14 Optimally, SMEDDSs and U-type preconcentrate are clear and transparent 
isotropic systems, which have the ability to produce o/w microemulsion systems when 
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in contact with aqueous media (ie, the gastrointestinal 
fluid) under gentle agitation (ie, digestive motility of the 
stomach and intestines), which would be advantageous 
in resolving the problem of the deterioration of soft cap-
sules due to the water content of either w/o or o/w type 
microemulsions.15,16
A SMEDDS is used to form preconcentrates of sur-
factants, oil, cosolvents, so that the drug can be diluted 
with water or pH 1.2 simulated gastric acid when orally 
administered to form o/w microemulsions with droplet 
sizes within the nanosize range. Nanosized droplets formed 
this way have very high surface-to-volume ratios and are 
expected to solubilize the drug, speed up drug release, and, 
subsequently, improve the bioavailability17 as well as release 
the drug in a more reproducible manner, which is less 
dependent on the gastrointestinal physiology and feeding/
fasting state of the patient.18 SMEDDSs have been reported 
to improve the in vivo dissolution and therefore enhance the 
bioavailability of lipophilic drugs.6,19–25 Commercially avail-
able drugs that make use of SMEDDSs include cyclosporin 
A as well as preparations of ritonavir and saquinavir (HIV 
protease inhibitors).26,27 However, although the SMEDDS 
preconcentrates containing 10% celecoxib revealed by 
Subramanian et al were not fully dilutable and only formed 
fine o/w droplets upon dilution in an aqueous phase, the 
results of drug absorption in humans were very encourag-
ing, with a 1.32-fold increase in the relative bioavailability 
compared with a conventional dosage form.28 Moreover, 
unlike drug-free SMEDDS preconcentrates, when flur-
biprofen was loaded, the dilution mixtures generated by 
the SMEDDS preconcentrates containing either Tween® 
20 (ICI Americas Inc, Wilmington, DE) or Cremophor® 
EL (BASF Corp, Ludwigshafen,   Germany) with Capmul® 
PG8 (ABITEC Corp, Columbus, OH) produced emulsions 
with observed cloudiness, the particle size was greatly 
increased compared with that of drug-free microemulsions 
(~11–13 nm).29 This effect became more apparent as the 
drug loading was increased.
Fenofibrate (FFB), used to treat high-cholesterol and 
high-triglyceride levels, is a neutral lipophilic compound 
(log P = 5.24) with very low solubility (,0.5 mg/L).30   
A low dissolution rate in aqueous media (including gastro-
intestinal fluids) is expected, which will result in incomplete 
and irregular bioavailability after oral ingestion. Reduction 
in the particle size of FFB by a micronization process can 
improve its solubility and the bioavailability is subsequently 
increased.30 A new dosage form of FFB, called a suprabio-
available tablet, has been developed, which combines 
micronization technology and microcoating processes. 
In this way, the increase in the amount of drug dissolved 
in the aqueous medium of the gastrointestinal tract also 
improves the extent of absorption.31–33 Another type of 
formulation developed for FFB is a hard gelatin capsule 
with a semisolid content into which FFB is homogenously 
dispersed within a lipid excipient mixture supplemented with 
hydroxypropyl methyl cellulose. The resulting formulation 
has increased drug solubility and dissolution rates as well 
as improved oral bioavailability equivalent to micronized 
FFB formulations.34
A SMEDDS composed of LabrafacTM (Gattefossé, Lyon, 
France) CM10 (31.5%), Tween® 80 (ICI Americas Inc) 
(47.3%), and polyethylene glycol 400 (12.7%) was formu-
lated for FFB and produced significant reductions in serum 
lipid levels in Phases I and II of the Triton test compared 
with plain FFB.35 Based on the previous study,36 the authors 
of the present study were intrigued that microemulsifying 
SMEDDSs in an aqueous medium or gastrointestinal tract 
fluid could decrease the drug loading, causing the solubi-
lized FFB in the SMEDDS preconcentrate to precipitate. 
The authors wished to characterize how formulation factors 
of SMEDDSs affected the resultant drug particles for dis-
solution after microemulsification with aqueous medium 
or gastrointestinal tract fluid, which influenced the in vivo 
absorption. Thus, the main objective of this study was to 
characterize the in situ formation of nanocrystals and dis-
solution profiles of FFB from SMEDDSs containing an oil 
of medium-chain triglyceride (MCT), Myritol® 318, and 
nonionic surfactant mixture, D-α-tocopheryl polyethylene 
glycol 1000 succinate (TPGS) combined with Tweens for a 
lipophilic model drug, FFB, in terms of the formulation fac-
tors and dissolution conditions to optimally correlate them 
with in vivo oral absorption.
Experimental
Materials
Myritol 318 (C8/C10 triglycerides) (Cognis Ltd, Tokyo, 
Japan) was used as the oil phase. TPGS was purchased from 
  Eastman Chemical Company (Kingsport, TN, USA). FFB 
and fenofibric acid (FBA) were supplied from Sigma Aldrich 
(St Louis, MO). Tween 20 and 80 were purchased from E 
Merck (Darmstadt, Germany). Hard gelatin capsules were 
supplied by Shing Lih Fang Enterprise (Taichung, Taiwan). 
Tricor® 54 mg tablets (lot 028362E21; exp date 2005/03/01) 
were supplied by Abbott Laboratories (North Chicago, IL; 
manufactured by Laboratories Fournier, Chenôve, France). 
All materials were either pharmaceutical or reagent grade.
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Preparation and viscosity measurement 
of SMEDDS
The pseudoternary phase diagrams of the SMEDDSs 
  constructed previously14 comprised Myritol 318 and surfac-
tant mixtures (Smix) of TPGS/polysorbates (Tween 20 or 80), 
incorporating 10% FFB. Formulations for the SMEDDSs, 
either within or outside the microemulsion region, were 
selected; their preliminary physical characteristics are listed 
in Tables 1 and 2, respectively. The formulation components 
were accurately weighed into screw-capped glass tubes with 
water-tight closures and heated to approximately 80°C in 
a thermostat-controlled water bath. When all formulation 
components had been melted/liquefied, the mixtures were 
thoroughly vortex mixed until a homogeneous solution 
was obtained, which was then allowed to stand at room 
temperature. The viscosity of the SMEDDSs was measured 
with a viscometer (model DV-II+ viscometer, Brookfield 
Engineering Labs, Middleboro, MA) using an LV spindle 
set of sp16 at 37°C. The mixture of the SMEDDS was 
manually filled into size 1 transparent hard gelatin capsules 
Table 1 Formulation compositions and physical characteristics (appearance, mean particle size, and polydispersity index) of fenofibrate 
(FFB) self-microemulsifying drug delivery system (SMEDDS) composed of D-α-tocopheryl polyethylene glycol 1000 succinate (TPgS) 
as the surfactant and Tween® 20 (A, C, and E) or Tween® 80 (B, D, and F) as the cosurfactant at various oil/Smix ratios (A and B at 0.42, 
C and D at 0.25, and E and F at 0.11) and water contents (–1, –2, and –3)
Code Myritol® 
318 (mg)
TPGS/ 
Tween 20  
(mg)a
TPGS/ 
Tween 80  
(mg)a
H2O 
(μg)
Appearance Particle size (nm, PI)
12 h 1 week 10 rpm 25 rpm 50 rpm
A1 135.0 
(23.8%)
324.0  
(57.1%)
– 54.0 
(9.5%)
D, C PPT(+++*), C 351.2 ± 7.7  
(0.168 ± 0.027)
352.3 ± 7.8  
(0.206 ± 0.031)
267.3 ± 3.1  
(0.130 ± 0.027)
A2 135.0 
(25.0%)
324.0  
(60.0%)
– 27.0 
(5.0%)
D, C PPT(+++), C 370.6 ± 15.1  
(0.259 ± 0.031)
372.5 ± 6.7  
(0.251 ± 0.024)
258.0 ± 3.9  
(0.143 ± 0.033)
A3 135.0 
(26.3%)
324.0  
(63.2%)
– 0.0 
(0.0%)
D, C PPT(++*), C 373.6 ± 6.1  
(0.236 ± 0.028)
365.1 ± 6.4  
(0.188 ± 0.038)
291.0 ± 4.0  
(0.202 ± 0.023)
B1 135.0 
(23.8%)
– 324.0  
(57.1%)
54.0 
(9.5%)
D, C PPT(++*), C 245.5 ± 3.9  
(0.124 ± 0.032)
209.8 ± 2.7  
(0.098 ± 0.038)
190.1 ± 3.9  
(0.126 ± 0.029)
B2 135.0 
(25.0%)
– 324.0  
(60.0%)
27.0 
(5.0%)
D, C PPT(++*), C 262.2 ± 5.6  
(0.122 ± 0.036)
213.0 ± 3.2  
(0.120 ± 0.027)
173.2 ± 1.9  
(0.126 ± 0.027)
B3 135.0 
(26.3%)
– 324.0  
(63.2%)
0.0 
(0.0%)
D, C PPT(++), C 264.6 ± 2.7  
(0.134 ± 0.032)
226.9 ± 2.0  
(0.084 ± 0.031)
168.9 ± 4.1  
(0.136 ± 0.036)
C1 84.6 
(14.9%)
338.6  
(59.7%)
– 89.8 
(15.8%)
PPT(++++), C PPT(+++++), C – – –
C2 85.1 
(15.8%)
340.2  
(63.0%)
– 60.8 
(11.3%)
PPT(++++), C PPT(+++++), C – – –
C3 84.9 
(16.6%)
339.7  
(66.2%)
– 34.4 
(6.7%)
PPT(++), C PPT(+++), C – – –
D1 84.6 
(14.9%)
– 338.6  
(59.7%)
89.8 
(15.8%)
PPT(+++), Cl PPT(++++), Cl – – –
D2 85.1 
(15.8%)
– 340.2  
(63.0%)
60.8 
(11.3%)
PPT(+++), Cl PPT(++++), Cl – – –
D3 84.9 
(16.6%)
– 339.7  
(66.2%)
34.4 
(6.7%)
PPT(++), C PPT(+++), C – – –
E1 41.0 
(7.2%)
369.4  
(65.1%)
– 102.6 
(18.1%)
PPT(++++), C PPT(+++++), C – – –
E2 41.3 
(7.7%)
371.8  
(68.9%)
– 72.9 
(13.5%)
PPT(++++), C PPT(+++++), C – – –
E3 41.3 
(8.1%)
371.8  
(72.5%)
– 45.9 
(8.9%)
PPT(+++), C PPT(++++), C – – –
F1 41.0 
(7.2%)
– 369.4  
(65.1%)
102.6 
(18.1%)
PPT(+++), S PPT(++++), S – – –
F2 41.3 
(7.7%)
– 371.8  
(68.9%)
72.9 
(13.5%)
PPT(+++), SS PPT(++++), SS – – –
F3 41.3 
(8.1%)
– 371.8  
(72.5%)
45.9 
(8.9%)
PPT(+++), C PPT(+++), C – – –
Notes: aTPgS: Tween 20 or TPgS: Tween 80 of 1: 4; FFB: 54 mg, 10%. Degree of precipitation description: +; *, half degree of +.
Abbreviations: D, dissolved; C, clear; Cl, cloudy; S, solid; SS, semisolid; PPT, precipitation.
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to a weight of about 540 mg. The capsules were kept at 
ambient temperature.
Dissolution studies and particle 
characterization
The dissolution profiles of the FFB SMEDDS capsules 
were determined using the USP 25 dissolution apparatus II 
(VK7020S; Varian Inc, Palo Alto, CA) method. The dissolution 
media consisted of 500 mL of simulated   gastric fluid 
(pH 1.2). The temperature of the medium was maintained 
at 37.0°C ± 0.5°C, and the rotation speed was set to three 
different speeds of 10, 25, and 50 rpm, since rotation speeds 
of 75 and 100 rpm were found to result in an insignificant 
difference in the release rate. Samples (5 mL) were automati-
cally withdrawn at 0, 5, 10, 20, 30, 60, 90, 120, 180, and 
270 minutes and fresh medium replaced. The sample was 
then diluted with a threefold volume of absolute alcohol 
to achieve an appropriate linear concentration range and 
prevent the drug from precipitating. Samples were then 
measured spectrophotometrically at 287 nm (using a Jasco 
V-550 UV/VIS spectrophotometer; JASCO International Co, 
Ltd, Tokyo, Japan) to determine the amount of drug released. 
The average percentage drug dissolved at each sampling time 
(n = 3) was calculated after correcting for the cumulative 
amount removed in previous samples. The UV method for 
quantification of FFB was validated to ensure acceptable 
precision and accuracy for intra- and interday measurements 
(data not shown).
The mean particle size and polydispersity index of 
FFB particles in the portion of each sample were deter-
mined using a nanoparticle size analyzer (BIC 90 PLUS; 
Brookhaven Instruments, Holtsville, NY). Before the 
measurement, samples were diluted with double-distilled 
water to a suitable scattering intensity. Processing the 
fluctuating signal with a digital autocorrelator yielded the 
particle’s diffusion coefficient, from which the equivalent 
spherical particle size was calculated using the Stokes–
Einstein equation.
Table 2 Formulation compositions and physical characteristics (appearance, mean particle size, and polydispersity index [PI]) of 
fenofibrate (FFB) self-microemulsifying drug delivery system (SMEDDS) composed of D-α-tocopheryl polyethylene glycol 1000 succinate 
(TPgS) as the surfactant and Tween® 20 (g, M, O, S, and T) or Tween® 80 (H, P, R, U, and V) as the cosurfactant at various oil/Smix 
ratios (g and H at 1.38, M and P at 1.11, S and U at 0.9, T and V at 0.58, and O and R at 0.46) and the same water content (4.5%)
Code Myritol® 
318 (mg, %)
TPGS/ 
Tween 20  
(mg, %)a
TPGS/ 
Tween 80  
(mg, %)a
Oil/Smix Appearance Particle size (PI)
(12 hours)b (1 week)b 10 rpm 25 rpm 50 rpm
g 267.3  
(49.5%)
194.4  
(36.0%)
– 1.38 D, S PPT(*),  
SE(+++++)
– – –
M 243.0  
(45.0%)
218.7  
(40.5%)
– 1.11 D, S D, SE(++++) – – –
S 218.7  
(40.5%)
243.0  
(45.0%)
– 0.90 D, S PPT(+),  
SS(+++)
381.1 ± 14.9  
(0.236 ± 0.041)
347.9 ± 8.2  
(0.242 ± 0.020)
313.8 ± 9.3  
(0.198 ± 0.032)
N 194.4  
(36.0%)
267.3  
(49.5%)
– 0.73 D, C PPT(+*),  
SE(*)
407.2 ± 10.4  
(0.260 ± 0.020)
402.8 ± 12.1  
(0.230 ± 0.029)
379.2 ± 13.1 
(0.167 ± 0.041)
T 170.1  
(31.5%)
291.6  
(54.0%)
– 0.58 D, C D, C 416.7 ± 15.2  
(0.194 ± 0.047)
347.0 ± 7.3  
(0.144 ± 0.048)
293.0 ± 15.1 
(0.143 ± 0.032)
O 145.8  
(27.0%)
315.9  
(58.5%)
– 0.46 D, C PPT(++), C 368.3 ± 12.9  
(0.177 ± 0.025)
323.8 ± 8.7  
(0.177 ± 0.029)
279.2 ± 4.5  
(0.177 ± 0.033)
H 267.3  
(49.5%)
– 194.4  
(36.0%)
1.38 D, C PPT(+), C – – –
P 243.0  
(45.0%)
– 218.7  
(40.5%)
1.11 D, C PPT(+), C – – –
U 218.7  
(40.5%)
– 243.0  
(45.0%)
0.90 D, C PPT(+), C 397.2 ± 30.1  
(0.059 ± 0.030)
350.7 ± 14.5  
(0.101 ± 0.043)
353.9 ± 17.1 
(0.129 ± 0.042)
Q 194.4  
(36.0%)
– 267.3  
(49.5%)
0.73 D, C PPT(++), C 487.5 ± 19.5  
(0.114 ± 0.049)
354.2 ± 14.0  
(0.185 ± 0.046)
280.1 ± 5.3  
(0.193 ± 0.031)
V 170.1  
(31.5%)
– 291.6  
(54.0%)
0.58 D, C D, C 418.2 ± 9.0  
(0.131 ± 0.038)
267.6 ± 5.8  
(0.201 ± 0.021)
223.1 ± 2.8  
(0.161 ± 0.026)
R 145.8  
(27.0%)
– 315.9  
(58.5%)
0.46 D, C PPT(++), C 285.4 ± 7.8  
(0.115 ± 0.036)
221.9 ± 5.6  
(0.098 ± 0.025)
204.5 ± 2.1  
(0.156 ± 0.033)
Notes: aTPgS: Tween 20 or TPgS: Tween 80 of 1: 4; FFB: 54 mg, 10%; H2O: 24.3 mg, 4.5%; total weight: 540 mg. Degree of precipitation description: +; *, half degree of +.
Abbreviations: D, dissolved; C, clear; SE, separated; SS, semisolid; PPT, precipitation.
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Pharmacokinetic studies
Healthy volunteers were recruited after signing an informed 
consent agreement approved by the Ethics Committee of 
Taipei Medical University Hospital. A parallel design was 
conducted with four subjects for each treatment of three 
formulations (SMEDDS B2 and Q, and a B2 solution) at 
the same strength (54 mg). After dosing, blood samples 
(10 mL) were collected in BD Vacutainers™ (Becton, 
Dickinson and Company, Franklin Lakes, NJ) containing 
K3EDTA by means of an indwelling venous cannula in the 
cubital vein according to a predetermined time schedule, 
which included a blank sample, just before dosing and 
then samples at 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, and 
60 hours after dosing. Plasma was immediately separated 
by centrifugation at 1690 g for 10 minutes, then transferred 
to suitably labeled tubes, and stored at –80°C until analysis. 
The plasma drug concentration was assayed with the vali-
dated high-performance liquid chromatographic (HPLC) 
method described below.
The HPLC system consisted of an Intelligent HPLC pump 
(PU-980; JASCO), an autosampler (AS-1555–10; JASCO), 
an UV/VIS detector (UV-975; JASCO), and a column oven 
(40°C). A column of Gemini® C18 110A (Phenomenex, Inc, 
Torrance, CA) (5 µm, 150 × 4.6 mm) was employed with a 
mobile phase consisting of acetonitrile:H2O:acetic acid of 
55:45:0.2 (v/v, %) at a flow rate of 1 mL/minute. The   eluent 
was monitored with a UV detector at a wavelength of 287 nm. 
Ketoprofen (40 µg/mL) was used as the internal standard. 
FBA, a major in vivo metabolite of FFB and used as a standard, 
was prepared with the solvent mixture of acetonitrile:H2O 
of 4:1 in the concentration range of 0.1, 0.2, 0.5, 1.0, 2.0, 
and 5.0 µg/mL, and three quality control (QC) samples of 
0.3, 2.5, and 4.0 µg/mL were dispensed in the same solvent 
mixture. Standard curves were constructed by adding 50 µL 
each of freshly prepared standard solutions and the internal 
standard stock solution to 0.5 mL of plasma in a 10 mL 
screw-top test tube. Plasma samples were then deproteinated 
by adding 0.1 mL of acetonitrile:70% perchloric acid at 1:1 
and briefly vortexed for 1 minute. The sample mixtures were 
centrifuged at 1690 g for 10 minutes at 4°C. The supernatant 
aqueous layer was pipetted out, and 400 µL was injected into 
a column for the HPLC analysis. Based on plasma profiles, 
all parameters of the pharmacokinetic study as defined were 
calculated using noncompartmental models for the period 
of 0–60 hours. The maximum concentrations (Cmax) and 
the time to reach Cmax (Tmax) were determined from the 
respective observed plasma concentrations versus time data. 
  The elimination rate constant (ke) was obtained by linear 
regression analysis of at least three sampling points of the 
terminal log-linear declining phase to the last measurable 
concentration. The elimination half-life (T1/2) was calculated as 
ln2/ke. The area under the curve (AUC) to the last measurable 
concentration (AUC0–last) was calculated by the linear trap-
ezoidal rule. The apparent oral clearance (Cl) was calculated 
as Dose/AUC0–inf and the mean residence time was calculated 
as AUMC0–inf/AUC0–inf. The relative bioavailability (F%) 
was calculated as AUC0–60,sample/AUC0–60,Tricor × 100. Results 
of inter- and intraday validations indicated that the correla-
tion coefficients were all .0.999, and the variabilities of the 
slopes and intercepts were all ,5% for all calibration curves 
constructed from the inter- and intraday assays. The relative 
standard error (RSE%) and coefficient of variation (CV%) 
were better than 20% at the lower limit of quantification (0.1 
µg/mL) and better than 15% at the remaining concentrations 
in both the intra- and interday analyses.
Statistical analysis
All results are presented as the mean ± standard deviation 
(SD). A one-way analysis of variance (ANOVA) was used to 
determine statistical significance of particle size, time when 
50% drug released, and pharmacokinetic parameters between 
groups (PASW Statistics 18.0; IBM Corp, Armonk, NY), and 
P , 0.05 was considered to be statistically significant.
Results and discussion
Physical characterizations of the SMEDDS 
formulations
The solubility of FFB is known to vary with those compo-
nents employed to formulate SMEDDSs examined in this 
study. It has been reported that 1 g of Myritol 318 could dis-
solve 94.14 ± 3.15 mg/g of FFB. The solubilities of FFB in 
10% TPGS, 10% Tween 20, and 10% Tween 80 solutions were 
1.56 ± 0.08, 0.52 ± 0.01, and 0.80 ± 0.02 mg/g, respectively.36 
Thus, the physical characteristics, including the appearance 
and solution status, of the SMEDDS formulations composed 
of Myritol 318 as the oil phase and TPGS/Tween 20 or 80 
as the surfactant/cosurfactant at the same level of 10% FFB 
based on the pseudoternary phase diagrams as reported 
previously14 were examined to select those SMEDDSs 
with optimal solubility for further evaluation. The detailed 
compositions of the two groups (Group I with various lower 
levels of oil/Smix ratios: A and B of 0.42, C and D of 0.25, 
and E and F of 0.11 and water contents: 0.0%, 5.0%, and 
9.5%; Group II with various higher levels of oil/Smix ratios: 
G and H of 1.38, M and P of 1.11, S and U of 0.9, T and V 
of 0.58, and O and R of 0.46 and the same water content of 
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4.5%) of SMEDDS formulations containing either TPGS/
Tween 20 or 80 are listed in Tables 1 and 2, respectively. 
For Group I (formulations A–F), it was found that only the 
A and B series of SMEDDS formulations maintained a dis-
solved status with no precipitation of FFB at 12 hours after 
preparation. Whereas, 1 week after preparation, FFB was 
observed to have precipitated out to a small extent in both A 
and B series of SMEDDS formulations but at a higher extent 
from the other formulations (C–F) in this group. For Group II 
with a higher oil/Smix ratio (formulations G–O containing 
Tween 20 and formulations H–R containing Tween 80), FFB 
was completely dissolved in SMEDDS formulations using 
either Tween 20 or 80 as the cosurfactant at all oil/Smix ratios 
12 hours after preparation, but phase separation was only 
observed for those SMEDDS formulations containing 
the Tween 20 at the higher oil/Smix ratio (formulations 
G, M, and S). At 1 week after preparation, FFB was found to 
have precipitated from all SMEDDS formulations containing 
either Tween 20 or 80, with the former showing a greater level 
of precipitation than the latter, except the SMEDDS formula-
tions of T (containing Tween 20) and V (containing Tween 
80) at an oil/Smix ratio of 0.58, which maintained complete 
dissolution with no phase separation.
In vitro dissolution characterizations
Those SMEDDS formulations selected above were further 
subjected to dissolution studies excluding formulations C, D, 
E, and F in Group I, for which severe FFB precipitation was 
observed 1 week after preparation, and formulations G, M, H, 
and P in Group II. For the first two, Tween 20 as the cosur-
factant was insufficient for a higher level of oil content to be 
microemulsified into a single phase, and Tween 80 was the 
cosurfactant at the same oil/Smix ratio as formulations G and 
M in the latter two.
Particle size characterizations
The results of mean particle size versus time profiles at three 
stirring rates are illustrated in Figures 1 and 2, respectively, for 
Group I (series A and B) and II (Tween 20 series: N, O, S, and T; 
Tween 80 series: Q, R, U, and V) SMEDDS formulations. 
The corresponding mean size and their size distributions 
expressed by the polydispersity index for the last time point 
of the dissolution study are listed in Table 1. Comparing 
series A and B SMEDDS formulations at three stirring rates 
(Figure 1) showed that FFB drug particles formed within the 
nanosize range gradually increased with time but decreased 
with an increase in the stirring rate at the same time point for 
both series. A minor difference was shown in the size of the 
FFB drug particles formed by these SMEDDS formulations 
containing various water contents within the same series. 
However, the mean particle size of FFB formed by the series 
B was as small as 200 nm, which was smaller than the cor-
responding SMEDDS formulations of series A at all three 
stirring rates. Similar results were observed for the particle 
characteristics determined for the final sampling time point, 
as shown in Table 1. It was concluded that for those formula-
tions within the SMEDDS region, Tween 80 was better than 
Tween 20 for precipitating FFB in SMEDDS formulations 
to form drug particles in a smaller size range. This effect was 
dependent on the stirring rate but independent of the water 
content. Because the hydrophilic–lipophilic balance value 
of Tween 80 (15) was lower than that of Tween 20 (16.7), it 
was expected that Tween 80 would have a higher capacity to 
solubilize FFB than Tween 20 resulting in the precipitation 
of FFB in a smaller nanosize range than those SMEDDSs 
containing Tween 80 as the cosurfactant.
Comparing the Tween 20 (N, O, S, and T) and Tween 80 series 
(Q, R, U, and V) of SMEDDS formulations in Group II at three 
stirring rates (Figure 2) also demonstrated that FFB drug 
particles formed within a similar nano-size range gradually 
increased with time except for the N formulation at the two 
higher stirring rates, but decreased with increasing stirring 
rates at the same time point for both series. A decrease was 
shown in the mean particle size of FFB particles formed from 
those SMEDDS formulations with a decreasing oil/Smix ratio 
within the same series except for formulation S in the Tween 20 
series at all three stirring rates, and   formulation U in the Tween 
80 series at the lowest stirring rate of 10 rpm. However, the 
mean particle size of FFB formed by the Tween 80 series 
reached the 200 ∼ 300 nm range at the highest stirring rate of 
50 rpm, which was smaller than the corresponding SMEDDS 
formulations of the Tween 20 series at the same stirring rate 
except for formulation Q in the Tween 80 series at the lowest 
stirring rate of 10 rpm. Similar results were observed for the 
particle characteristics determined for the final sampling time 
point as demonstrated in Table 2. Because formulation S of 
the Tween 20 series was unable to form a SMEDDS leading 
to phase separation as demonstrated in Table 2, the portion 
of FFB which dissolved in the oil phase separated from the 
SMEDDS during dissolution, causing a smaller amount of FFB 
to be precipitated and form drug particles with a smaller mean 
size than for the other formulations of the Tween 20 series. 
On the other hand, a larger mean size of FFB particles formed 
from formulation Q at the lowest stirring rate of 10 rpm could 
be attributed to the higher viscosity of Tween 80 at a higher 
oil/Smix ratio of 0.73, which increased the droplet size of the 
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microemulsified internal phase. Rationally, this viscosity effect 
on the formation of droplet size of the internal phase was only 
significant at a lower stirring rate (P , 0.001).
Dissolution profile characterizations
The drug released (%) from those SMEDDS formulations 
in the dissolution study was measured after dilution by 
the addition of absolute alcohol to dissolve those FFB 
nanoparticles in the dissolution medium to an appropriate 
concentration range. Figures 3 and 4, respectively, illustrate 
the release profiles for Groups I (series A and B) and II 
(Tween 20 series: N, O, S, and T; and Tween 80 series: Q, 
R, U, and V) at three stirring rates. As shown in Figure 3, the 
release rates from both series A and B SMEDDSs obviously 
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Figure 1 Dissolution profiles of fenofibrate (FFB) from self-microemulsifying drug delivery system (SMEDDS) formulations composed of D-α-tocopheryl polyethylene glycol 
1000 succinate (TPgS) as the surfactant and Tween® 20 (A1, A2, and A3) or Tween® 80 (B1, B2, and B3) as the cosurfactant at various stirring rates: (A) 10 rpm, (B) 25 rpm, 
(C) 50 rpm.
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increased with an increasing stirring rate (P , 0.001 for 
series A and P = 0.003 for series B). At the lower stirring 
rate of 10 rpm (Figure 3A), the release rate from series A 
seemed to decrease with an increasing water content (A1 
[9.5%] , A2 [5.0%] , A3 [0.0%]), whereas that from series B 
followed an opposite trend (B1 [9.5%] ≅ B2 [5.0%] . B3 
[0.0%]). Further, only the release rate from series B contain-
ing 0% water content (B3) was slower than that from the 
corresponding series A containing the same water content. 
With an increase in the stirring rate to 25 rpm (Figure 3B), 
no difference was   evident among the release rates from 
series B (P = 0.896), and all were faster than those from the 
corresponding series A formulations with the same water 
content. The release rate from A3 was a little faster than those 
from A1 and A2. With a further increase in the stirring rate to 
50 rpm (Figure 3C), the release rates from series A were in the 
order of A1 ≅ A2 . A3, whereas those from series B were 
in the order of B3 . B2 ≅ B1, all of which were slower than 
those from the corresponding series A containing the same 
water content.
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Figure 2 Dissolution profiles of fenofibrate (FFB) from self-microemulsifying drug delivery system (SMEDDS) formulations composed of D-α-tocopheryl polyethylene glycol 
1000 succinate (TPgS) as the surfactant and Tween® 20 (N, O, S, and T) or Tween® 80 (Q, R, U, and V) as the cosurfactant at various oil/Smix ratios (S and U at 0.9, N and 
Q at 0.73, T and V at 0.58, and O and R at 0.46) with the same water content (4.5%) at various stirring rates: (A) 10 rpm, (B) 25 rpm, (C) 50 rpm.
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but no significant difference was shown among the release 
rates for the Tween 80 series examined (P = 0.758). Before 
the drug concentration was measured, the sampled dissolution 
medium was diluted with absolute alcohol, which possesses 
good solubility for FFB; thus, all drug particles existing in the 
dissolution medium would have been completely dissolved, 
meaning no differences in the amount released, even though 
different mean particle sizes were observed for the Tween 
80 series in the respective dissolution medium. This result 
also implies that, at the same stirring rate, the microemul-
sification of those SMEDDSs of the Tween 80 series had to 
have reached the same extent to achieve the same amount 
of drug existing in the dissolution medium and for the same 
amount released to be measured.
Pharmacokinetic studies
Two optimal SMEDDSs were selected for the pharma-
cokinetic study conducted with a parallel design: one 
contained Tween 80 (B2[SMEDDS]) or a higher oil/Smix 
ratio (Q[SMEDDS]) at a dosing strength of 54 mg FFB in 
capsule form, and the B2(solution) was prepared by dissolv-
ing B2 SMEDDS in the same volume of water (250 mL) as 
that usually taken with oral administration. The resultant 
plasma profiles for the three treatments (B2[SMEDDS], 
Q[SMEDDS], and B2[solution]) and that for Q(SMEDDS) 
compared with that for A2(SMEDDS) and Tricor con-
ducted in a previous study36 are illustrated in Figure 5A 
and B, respectively, and the corresponding calculated 
pharmacokinetic parameters are listed in Table 3. Results 
demonstrated that the AUC and Cmax  values  were 
ranked in the order of Q(SMEDDS) . B2(solution) . 
B2(SMEDDS) and B2(solution) . Q(SMEDDS) . B2(SM
EDDS), respectively, for this study, whereas overall both the 
AUC and Cmax values were ranked, respectively, in the order 
of Q(SMEDDS) . Tricor ≅ B2(solution) . B2(SMEDDS) 
≅ A2(SMEDDS) and B2(solution) . Q(SMEDDS) . Tricor 
≅ B2(SMEDDS) . A2(SMEDDS). These results indicate 
that the overall relative bioavailability based on either 
AUC0–last or AUC0–inf with respect to Tricor for Q(SMEDDS) 
was enhanced approximately 1.14–1.22-fold. The relative 
bioavailabilities of A2(SMEDDS) and B2(SMEDDS) were 
similar but less than that for B2(solution), which was close 
to that for Tricor. Furthermore, as indicated by the large 
Cmax value and the short Tmax, the in vivo absorption rate 
for B2(solution) was the fastest of all, followed in order by 
Q(SMEDDS) . Tricor ≅ B2(SMEDDS) . A2(SMEDDS).
As indicated by the particle sizes at the three stirring 
rates shown in Table 1, the fastest in vivo absorption rate for 
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Figure 3 Mean particle size profiles of fenofibrate (FFB) from self-microemulsifying 
drug  delivery  system  (SMEDDS)  formulations  composed  of  D-α-tocopheryl 
polyethylene  glycol  1000  succinate  (TPgS)  as  the  surfactant  and  Tween®  20 
(A1, A2, and A3) or Tween® 80 (B1, B2, and B3) as the cosurfactant at various 
stirring rates: (A) 10 rpm, (B) 25 rpm, (C) 50 rpm.
Similarly, as shown in Figure 4, the release rates from both 
Tween 20 series (N, O, S, and T) and Tween 80 series (Q, R, 
U, and V) of SMEDDSs increased with an increasing stirring 
rate. Among the Tween 20 series, incomplete release was 
observed only for the S and N SMEDDSs at all three stirring 
rates. As described above, this was attributed to a failure of 
the S and N formulations to microemulsify all of the oil phase 
in which most of the FFB was dissolved.   However, a faster 
release rate and complete release were observed for the Tween 
80 series of SMEDDSs compared with the Tween 20 series, 
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B2(solution) can potentially be attributed to the formation 
of a particle size in the smallest range for the B2 solution 
when the B2 SMEDDS was dissolved in water, making it 
readily available for absorption. After oral administration, 
the three SMEDDSs (A2, B2, and Q) would take some time 
for the microemulsification to dissolve before the FFB was 
available for absorption. Further, the mean particle size after 
microemulsification at the three different stirring rates for 
B2(SMEDDS) were all smaller than that for A2(SMEDDS). 
This can be explained by the fact that the in vivo absorption 
rate for B2(SMEDDS) was faster than that for A2(SMEDDS). 
Nevertheless, this particle size effect could not be explained 
by the in vivo absorption rate for Q(SMEDDS) being faster 
than that for B2(SMEDDS). Perhaps the oil content in the 
higher oil/Smix ratio of Q(SMEDDS) played a role as a car-
rier providing an additional oral absorption route, such as 
via the lymph system, to increase the in vivo absorption 
rate.16 But the time required for microemulsification of 
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Table 3 Mean pharmacokinetic parameters for B2 and Q self-microemulsifying drug delivery system (SMEDDS) and B2 solution 
compared with A2 SMEDDS and Tricor® tablets conducted in a previous study36
PK 
parameters
B2 solution B2 SMEDDS Q SMEDDS A2 SMEDDS Tricor
AUC0–last (µg/mL ⋅ h) 67.02 ± 20.62 46.85 ± 19.17 79.48 ± 5.20 44.81 ± 14.13 69.75 ± 12.60
AUC0–inf (µg/mL ⋅ h) 78.31 ± 31.08 51.66 ± 22.65 106.84 ± 20.38 52.66 ± 19.23 87.03 ± 22.04
MRT0–inf (h) 27.06 ± 9.78 22.54 ± 4.40 42.85 ± 18.19 26.30 ± 9.38 35.15 ± 8.30
Kel (h–1) 0.036 ± 0.009 0.040 ± 0.008 0.025 ± 0.010 0.039 ± 0.013 0.027 ± 0.01
T1/2 (h) 20.28 ± 5.82 17.94 ± 3.16 32.04 ± 13.58 19.73 ± 6.99 26.43 ± 5.67
CL/F (L/h) 0.78 ± 0.33 1.21 ± 0.52 0.52 ± 0.10 1.14 ± 0.43 0.65 ± 0.17
Vd/F (L) 21.11 ± 3.95 31.01 ± 15.25 22.71 ± 5.70 29.49 ± 3.39 23.92 ± 2.66
Tmax (h) 1.25 ± 0.50 2.00 ± 0.82 1.75 ± 0.50 3.00 ± 1.41 2.75 ± 0.50
Cmax (µg/mL) 4.29 ± 0.62 3.21 ± 1.05 3.74 ± 0.52 2.62 ± 0.47 3.27 ± 0.61
Bioavailability (%)* 96.1 (90.0) 67.2 (59.4) 114.0 (122.8) 64.2 (60.5) 100.0 (100.0)
Note: *Relative bioavailability with respective to Tricor based on AUC0–last or (AUC0–inf).
Abbreviations: AUC, area under the curve; MRT, mean resistance time; PK, pharmacokinetic.
Q(SMEDDS) in the gastrointestinal tract might cause some 
reduction in its in vivo absorption rate compared with the 
B2(solution), which was completely microemulsified before 
oral administration.
The oral bioavailability of B2(solution) was slightly 
lower than that for Tricor, but both were lower than that for 
Q(SMEDDS), and greater than those for B2(SMEDDS) and 
A2(SMEDDS), which did not significantly differ (P = 0.058). 
This result seems to indicate that the expected difference 
in the mean particle size after oral administration between 
B2(SMEDDS) and A2(SMEDDS) as deduced from the 
in vitro dissolution results did affect the in vivo absorption rate 
but not the oral bioavailability. However, the oral bioavailabil-
ity of the B2(solution) formulated by completely microemul-
sifying B2(SMEDDS) in the same volume of water as that 
usually taken with oral administration was greater than that 
for B2(SMEDDS) and only slightly lower than that for Tricor. 
Therefore, this result might be attributed to the incomplete 
microemulsification of B2(SMEDDS) and A2(SMEDDS) 
in the gastrointestinal tract leading to a lower bioavailability 
compared with B2(solution) that was completely microemul-
sified before oral administration. As discussed above, the oil 
content in a higher oil/Smix ratio of Q(SMEDDS) probably 
acted as a carrier to provide a favorable additional oral absorp-
tion route, such as the lymphatic system, which enhanced 
both the in vivo absorption rate and the oral bioavailability. 
Therefore, Q(SMEDDS) with an appropriate ratio of oil/Smix 
presented the highest oral bioavailability of all SMEDDSs 
examined and even had an approximately 1.14–1.22-fold 
higher enhancement over Tricor.
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Conclusion
An optimal SMEDDS preconcentrate consisting of Myritol 
318 (a medium-chain triglyceride) as the oil phase and TPGS 
combined with Tween 80 at a ratio of 4:1 as the surfactant/
cosurfactant, was able to enhance the oral bioavailability 
of FFB. Tween 80 was better than Tween 20 in forming 
smaller particles, which enhanced the in vivo absorption rate 
by increasing the surface area available for drug dissolution 
but had little influence on the oral bioavailability due to the 
lower extent of microemulsification. With a higher oil/Smix 
ratio exceeding 0.46, the microemulsification effectiveness 
(rate) was enhanced making drug particles readily available 
for absorption at any in vivo agitation rate; the oral bio-
availability was improved with the favorable role Myritol 
318 might play as a carrier by providing an additional oral 
route of the lymphatic system for FFB absorption.
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